Context Therapeutics is building up its bank of bispecific antibody candidates. | Context Therapeutics is building up its ...

Black Diamond Therapeutics and Ideaya Biosciences are mulling over registrational trials for their lead assets after ...

The Sanofi equity investment means the Big Pharma will receive exclusive rights of first negotiation surrounding VTX3232, an ...

The stroke devicemaker Route 92 Medical has raised $50 million in funds, as it looks to expand the worldwide commercial reach ...

Troriluzole failed a phase 3 trial in spinocerebellar ataxia in 2022. Based on talks with the FDA, Biohaven kept tracking ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

The respiratory syncytial virus (RSV) space may have filled up over the past year, but that isn’t deterring Vicebio or its ...

Courtney Walker, Chief Growth Officer at MMC and RXMosaic, discusses the evolving role of communicators and the future of the healthcare industry. AI will significantly transform the field, ...

Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...

After CEO Kevin Lobo promised earlier this summer a “bullish” M&A pipeline, Stryker is following through with its seventh ...

In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...

Medtronic is offering a peek into its ongoing, at-home trial of people with Parkinson’s disease being treated with adaptive ...